Jason P. Rhodes - 30 May 2025 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Director
Signature: /s/ Ommer Chohan, Attorney-in-Fact
Issuer symbol: DYN
Transactions as of: 30 May 2025
Transactions value $: $0
Form type: 4
Filing time: 03 Jun 2025, 21:39:24 UTC
Previous filing: 29 Jan 2025
Next filing: 06 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rhodes Jason P	Director	C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM	/s/ Ommer Chohan, Attorney-in-Fact	03 Jun 2025	0001577014

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock option (right to buy)	Award	$0	+35K		$0.00	35K	30 May 2025	Common Stock	35K	$11.96	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
F2	The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Content

This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.